

B2 3) The process of claim 1 wherein the polymer is selected from the group consisting of nucleic acids, [proteins, ]genes, [antisense polymers, ]DNA/RNA hybrids, synthetic polymers.

6) The process of claim 1 [2] wherein the [first] polymer comprises a nucleic acid.

7) The process of claim 1 [6] wherein the [second polymer] associated polymer and chelator consists of [comprises] a net [positive] charge selected from the group consisting of positive, neutral and negative.

8) The process of claim 7 wherein the chelator consists of [comprises] polyamine.

9) The process of claim 1 further comprising associating a chelator with a polymer and a signal for targeting the polymer.

10) [A process for compacting a nucleic acid for delivery to a cell, comprising:  
associating a polychelator with a nucleic acid.]

B3 A process for delivering a polymer to a cell, in vivo, comprising:

a) forming a polychelator by covalently polymerizing chelator monomers;

b) electrostatically associating the polychelator with the polymer to form a complex;

c) delivering the polymer to the cell; and,

d) expressing the polymer.

11) [The complex of claim 10 wherein associating a polychelator further comprises associating a polychelator and a salt and a nucleic acid.]

The process of claim 10 wherein the polymer consists of nucleic acid and is condensed by associating the polychelator, nucleic acid and a salt.

12) [A complex for delivering a compound to a cell, comprising:

a) a nucleic acid;

b) a polychelator; and,

c) an ion.]

A process for delivering a polymer to a cell, comprising:

a) electrostatically associating a polychelator to the polymer;

b) recharging the polychelator to change the net charge; and,

c) delivering the polymer to the cell, *in vivo*.

B3  
cond  
13) [The complex of claim 12 wherein the complex is less than 500 nanometers in diameter.]

The process of claim 12 wherein the polymer is selected from the group consisting of  
nucleic acids, proteins, genes, antisense polymers, DNA/RNA hybrids, synthetic polymers.

14) The process of claim 13 wherein the polymer consists of a nucleic acid.

15) The process of claim 13 wherein the polychelator comprises a crown ether system.

16) The process of claim 12 wherein the associated polymer-polychelator comprises a net charge  
selected from the group consisting of positive, neutral and negative.

B4  
17) The process of claim 13 wherein a signal for targeting the polymer is attached to the chelator  
or polymer.

18) A process for delivering a nucleic acid to a cell, *in vivo*, comprising:

a) non-covalently associating a chelator with a nucleic acid to form a complex;

b) inserting the complex *in vivo*; and,

c) removing the chelator from the nucleic acid that is delivered to the cell.

19) A process for delivering a polymer to a cell comprising:

a. forming a complex consisting of an expressible polymer and a non-expressible polymer;

b. chelating the non-expressible polymer; and,

b. delivering the expressible polymer to the cell.